IPM Take
The lesson from PROTEUS is not simply “treat earlier.” It is “treat earlier, but choose carefully.” High-risk localized prostate cancer is not one uniform disease. Some patients need escalation before metastasis appears. Others may be exposed to more toxicity and cost than they need. The next implementation fight will be patient selection.
Executive Summary
Johnson & Johnson reported final phase III PROTEUS results showing that apalutamide plus androgen deprivation therapy, given before and after radical prostatectomy, improved key outcomes in patients with high-risk localized or locally advanced prostate cancer. Patients receiving apalutamide plus ADT were nine times more likely to have little to no cancer remaining in the prostate after surgery, and the regimen reduced the risk of metastasis or death by 20%. The results were selected for ASCO 2026 plenary presentation and published in The New England Journal of Medicine.
Why it matters
- Clinicians: Need to identify which high-risk patients benefit most from perioperative intensification.
- Payers / HTA bodies: Must assess value in a curative-intent setting where overtreatment is a real concern.
- Patients / advocates: Should push for shared decision-making that explains both recurrence risk and treatment burden.
Prostate cancer policy often becomes polarized between early detection, active surveillance and treatment escalation. PROTEUS sits in the middle of that tension. It targets the group where doing too little can be dangerous, but doing too much can also harm.
The trial studied high-risk localized or locally advanced prostate cancer in patients undergoing radical prostatectomy. Apalutamide plus ADT was used around surgery, not after metastatic spread. That matters because the treatment goal is different. The aim is not only to control advanced disease, but to prevent progression before the metastatic clock starts.
The result strengthens the case for earlier systemic therapy in selected high-risk patients. But it also makes the pathway more complicated. Risk stratification, imaging, pathology, genomic classifiers where available, patient preference and surgical planning may all become more important in deciding who should receive intensified perioperative treatment.
The eligible population is not all prostate cancer patients. It is a defined high-risk group, and that distinction should stay visible. Broad enthusiasm should not turn into blanket escalation.
For IPM, PROTEUS is a strong example of personalised implementation: the system must identify who is likely to benefit, deliver treatment at the right time, and avoid making early intensification a blunt policy instrument.
